HBI 26
Alternative Names: HBI-26Latest Information Update: 12 Jan 2024
At a glance
- Originator Human Biome Institute
- Class Antibacterials
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Clostridium difficile infections
Most Recent Events
- 29 Nov 2023 Preclinical trials in Clostridium difficile infections in Poland (unspecified route) (Human Biome Institute pipeline, November 2023)